Wittekind Amends Renovaro Inc. 13D Filing

Ticker: LNAI · Form: SC 13D/A · Filed: Apr 8, 2024 · CIK: 1527728

Renovaro Inc. SC 13D/A Filing Summary
FieldDetail
CompanyRenovaro Inc. (LNAI)
Form TypeSC 13D/A
Filed DateApr 8, 2024
Risk Levelmedium
Pages7
Reading Time8 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: 13D-filing, ownership-change, amendment

Related Tickers: RENO

TL;DR

Wittekind updated his stake in Renovaro Inc. (RENO) via 13D amendment.

AI Summary

William Anderson Wittekind filed an amendment (No. 15) to Schedule 13D on April 8, 2024, for Renovaro Inc. The filing indicates a change in beneficial ownership of the company's common stock. Wittekind's address is listed as 8581 Santa Monica Blvd. #317, West Hollywood, CA 90069.

Why It Matters

This filing signals a potential shift in control or significant stake changes for Renovaro Inc., which could impact its stock price and strategic direction.

Risk Assessment

Risk Level: medium — Schedule 13D filings often indicate significant ownership changes, which can lead to volatility and strategic shifts for the company.

Key Players & Entities

  • William Anderson Wittekind (person) — Filing party and beneficial owner
  • Renovaro Inc. (company) — Subject company
  • 29350E 104 (other) — CUSIP Number for Renovaro Inc. common stock

FAQ

What specific changes in beneficial ownership are detailed in Amendment No. 15?

The filing is an amendment to Schedule 13D, indicating a change in beneficial ownership, but the specific details of the change (e.g., number of shares, percentage) are not provided in the header information.

When was Amendment No. 15 filed?

Amendment No. 15 was filed on April 8, 2024.

Who is the filing party for this Schedule 13D amendment?

The filing party is William Anderson Wittekind.

What is the CUSIP number for Renovaro Inc. common stock?

The CUSIP number for Renovaro Inc. common stock is 29350E 104.

What was Renovaro Inc. formerly known as?

Renovaro Inc. was formerly known as Renovaro Biosciences Inc., Enochian Biosciences Inc., and Renovaro Biosciences Inc. again, with name changes occurring on August 7, 2023, August 4, 2023, and August 2, 2023, respectively.

Filing Stats: 2,102 words · 8 min read · ~7 pages · Grade level 9.7 · Accepted 2024-04-08 17:44:51

Key Financial Figures

  • $0.0001 — ame of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 29350

Filing Documents

Purpose of Transaction

Item 4. Purpose of Transaction The information in Item 6 of this Amendment No. 15 is hereby incorporated by reference into this Item 4.

Interests in Securities

Item 5. Interests in Securities of the Issuer (a)-(b) The information in Items 7-11 and Item 13 of the cover page of this Amendment No. 13, including the accompanying footnotes, is hereby incorporated by reference into this Item 5. (c) None. (d) Not applicable. (e) Not applicable.

. Contracts, Arrangements, Understandings

Item 6 . Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer. Rule 11 Opposition On April 4, 2024 legal counsel for Weird Science and Wittekind filed an Opposition to Motion for Sanctions (the “ Rule 11 Opposition ”) with the United States District Court for the Central District of California–Western Division (the “ California District Court for the Central District ”). The Rule 11 Opposition is attached to this Amendment No. 15 as Exhibit 17 and the Declaration of Legal Counsel for Weird Science in Support of the Rule 11 Opposition is attached to this Amendment No. 15 as Exhibit 18. 3 Rule 11 Motion The Rule 11 Opposition opposes the Motion for Sanctions (the “ Rule 11 Motion ”) filed by legal counsel for Rene Sindlev, Mark Dybul, Gregg Alton, Carol Brosgart, Henrik Gronfeldt-Sorensen, James Sapirstein and Jayne McNicol (together, the “ Board Defendants ”) in connection with the Verified Stockholder Derivative Complaint and the Ex Parte Application for a Temporary Restraining Order filed by Weird Science and Wittekind with the California District Court for the Central District on January 23, 2024. The Rule 11 Motion is attached to this Amendment No. 15 as Exhibit 19, the Declaration of Mark Dybul in Support of the Rule 11 Motion is attached to this Amendment No. 15 as Exhibit 20, and the Declaration of Legal Counsel for the Board Defendants in Support of the Rule 11 Motion is attached to this Amendment No. 15 as Exhibit 21. Stockholder Derivative Complaint A hearing for the Rule 11 Motion has been scheduled for April 25, 2024. Once the Rule 11 Motion is adjudicated, Weird Science and Wittekind intend to evaluate the claims related to the Stockholder Derivative Complaint and proceed accordingly. Termination of Weird Science License Agreement As reported in the Issuer’s Form 8-K filed on March 7, 2024, Wittekind, on behalf of Weird Science in hi

View Full Filing

View this SC 13D/A filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.